Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD)
Standard
Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD). / Schwedhelm, Edzard; Englisch, Catrin; Niemann, Louisa; Lezius, Susanne; von Lucadou, Mirjam; Marmann, Kristina; Böger, Rainer; Peine, Sven; Daum, Günter; Gerloff, Christian; Choe, Chi-Un.
In: MOVEMENT DISORD, Vol. 36, No. 9, 09.2021, p. 2178-2182.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD)
AU - Schwedhelm, Edzard
AU - Englisch, Catrin
AU - Niemann, Louisa
AU - Lezius, Susanne
AU - von Lucadou, Mirjam
AU - Marmann, Kristina
AU - Böger, Rainer
AU - Peine, Sven
AU - Daum, Günter
AU - Gerloff, Christian
AU - Choe, Chi-Un
N1 - © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
PY - 2021/9
Y1 - 2021/9
N2 - BACKGROUND: Treatment with sphingosine-1-phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD).OBJECTIVES: We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD.METHODS: S1P concentrations were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in serum of 196 PD patients and in 196 age- and sex-matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow-up data was available from 64 patients (median [interquartile range], 513 [381-677] days).RESULTS: S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38-2.07) and 1.90 (1.59-2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow-up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening.CONCLUSIONS: Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
AB - BACKGROUND: Treatment with sphingosine-1-phosphate (S1P) agonists confers neuroprotective effects in animal models of Parkinson's disease (PD).OBJECTIVES: We assessed the association of serum S1P levels with motor and cognitive symptoms in patients with PD.METHODS: S1P concentrations were analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS) in serum of 196 PD patients and in 196 age- and sex-matched controls. Motor (Unified Parkinson's disease rating scale III [UPDRS III], Hoehn and Yahr) and cognitive (Montreal Cognitive Assessment [MoCA]) function were assessed at baseline. Follow-up data was available from 64 patients (median [interquartile range], 513 [381-677] days).RESULTS: S1P levels were lower in PD patients compared with controls, that is 1.75 (1.38-2.07) and 1.90 (1.59-2.18) μmol/L, respectively (P = 0.001). In PD patients, lower S1P concentrations were associated with higher UPDRS III scores and Hoehn and Yahr stage. In the follow-up cohort, S1P concentrations below the median were associated with faster motor decline (hazard ratio: 4.78 [95% CI, 1.98, 11.50]), but not with cognitive worsening.CONCLUSIONS: Our observations reveal an association of S1P with PD. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
U2 - 10.1002/mds.28652
DO - 10.1002/mds.28652
M3 - SCORING: Journal article
C2 - 34008894
VL - 36
SP - 2178
EP - 2182
JO - MOVEMENT DISORD
JF - MOVEMENT DISORD
SN - 0885-3185
IS - 9
ER -
